635 reports of this reaction
3.8% of all ROCURONIUM BROMIDE reports
#5 most reported adverse reaction
CARDIAC ARREST is the #5 most commonly reported adverse reaction for ROCURONIUM BROMIDE, manufactured by Fresenius Kabi USA, LLC. There are 635 FDA adverse event reports linking ROCURONIUM BROMIDE to CARDIAC ARREST. This represents approximately 3.8% of all 16,854 adverse event reports for this drug.
Patients taking ROCURONIUM BROMIDE who experience cardiac arrest should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CARDIAC ARREST is moderately reported among ROCURONIUM BROMIDE users, representing a notable but not dominant share of adverse events.
In addition to cardiac arrest, the following adverse reactions have been reported for ROCURONIUM BROMIDE:
The following drugs have also been linked to cardiac arrest in FDA adverse event reports:
CARDIAC ARREST has been reported as an adverse event in 635 FDA reports for ROCURONIUM BROMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
CARDIAC ARREST accounts for approximately 3.8% of all adverse event reports for ROCURONIUM BROMIDE, making it a notable side effect.
If you experience cardiac arrest while taking ROCURONIUM BROMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.